Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mauna Kea Technologies SAS Announces That First Cellvizio Optical Biopsy Probe Designed for Urological Applications is Now CE Marked


Wednesday, 5 Dec 2012 11:45am EST 

Mauna Kea Technologies SAS announced that its UroFlex confocal miniprobe received CE mark approval for use during cystoscopy procedures. UroFlex is the first optical biopsy probe designed for urological applications and allows the company to enter the EUR 1 billion European urology device market. The new probe allows physicians to obtain optical biopsies that may facilitate the diagnosis, surveillance and treatment of patients with bladder cancer. 

Company Quote

6.51
0.0 +0.00%
6:29am EDT